Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

592
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
592
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

468
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
468
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

606
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
606

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncologic outcomes and trends in each colon cancer location and stages over the last two decades: insights from the SEER registry.

Techniques in coloproctology·2024
Same author

Renal Autotransplantation in a Patient with Bilateral Renal Artery Stenosis Secondary to Takayasu Arteritis.

International journal of organ transplantation medicine·2020
Same author

Is There a Long-Term Risk for Donors With Heterozygous MEFV Mutation After Kidney Donation?

Transplantation proceedings·2017
Same author

Risk Factors of Hyperuricemia After Renal Transplantation and Its Long-term Effects on Graft Functions.

Transplantation proceedings·2017
Same author

Prevalence and Risk Factors of BK Viremia in Patients With Kidney Transplantation: A Single-Center Experience From Turkey.

Transplantation proceedings·2017
Same author

The effect of OK-432 (Picibanil) injection on the histopathology of nasal turbinate.

The Journal of laryngology and otology·2015

Related Experiment Video

Updated: Mar 5, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K

Average Tacrolimus Trough Level in the First Month After Transplantation May Predict Acute Rejection.

S Aktürk1, Ş Erdoğmuş1, G Kumru1

  • 1Department of Nephrology, Ankara University School of Medicine, Ankara, Turkey.

Transplantation Proceedings
|March 26, 2017
PubMed
Summary

Maintaining tacrolimus trough levels (TTLs) at 8 ng/mL or higher in the first month post-kidney transplant significantly reduces the risk of biopsy-proven acute rejection (BPAR). This target level helps prevent BPAR and minimizes drug toxicity.

More Related Videos

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
10:31

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model

Published on: August 13, 2017

8.1K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.7K

Related Experiment Videos

Last Updated: Mar 5, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.5K
Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
10:31

Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model

Published on: August 13, 2017

8.1K
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

16.7K

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Tacrolimus is crucial for preventing kidney transplant rejection, but optimal therapeutic trough levels remain unclear.
  • Early post-transplant monitoring is essential for managing immunosuppression efficacy and toxicity.

Purpose of the Study:

  • To investigate the association between average tacrolimus trough levels (TTLs) in the first month after kidney transplantation and the occurrence of biopsy-proven acute rejection (BPAR) within the first 12 months.
  • To establish a target TTL for minimizing BPAR risk in kidney recipients.

Main Methods:

  • Retrospective analysis of 274 kidney-alone transplant recipients (2002-2014).
  • Receiver operating characteristic (ROC) curve analysis to determine the optimal TTL threshold for BPAR prediction.
  • Univariate and multivariate Cox proportional hazards models to assess the impact of early TTLs on BPAR risk.

Main Results:

  • ROC analysis identified 8 ng/mL as the optimal threshold for average TTLs in the first month (AUC = 0.73).
  • Patients with average TTLs < 8 ng/mL had a significantly higher incidence of BPAR (31.8%) compared to those with TTLs ≥ 8 ng/mL (9.1%) (P < .001).
  • Lower early TTLs (< 8 ng/mL) were independently associated with a 2.79-fold increased risk of BPAR (P = .001).

Conclusions:

  • Targeting an average tacrolimus trough level of ≥ 8 ng/mL during the first month post-transplant is effective in preventing BPAR.
  • This target level may also help mitigate the potential toxic effects associated with immunosuppressive therapy.